Balanced news tone
News Sentiment
TCRT sentiment intelligence
Alaunos Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
47 relevant articles
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, -4.7% over four weeks, trend inactive, and below fair value.
Price to earnings forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Earnings
77/100 classification
One-week reaction
0.0%
Price digesting
Trend fit
Trend inactive
-4.7% over four weeks
Fair value
-73.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
8
Neutral
29
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingView
Direct company coverage
Price to earnings forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT
The article references the price to earnings forward of Alaunos Therapeutics, Inc. under the NASDAQ:TCRT ticker. It appears to be a financial data page from TradingView, indicating that the market for TCRT was closed with no trades. The content primarily consists of navigation an
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Jul 2026 17:41
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT
This article provides financial information for Alaunos Therapeutics, Inc. (NASDAQ: TCRT), specifically its Price to Book Forward value. The content is presented within the TradingView platform, noting that market data is provided by ICE Data Services and reference data by FactSe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jul 2026 19:11
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT
This article provides an enterprise value to revenue forward metric for Alaunos Therapeutics, Inc. (NASDAQ: TCRT). It focuses on financial data for the company, accessible through TradingView, and does not contain detailed analysis or news content. The piece appears to be a stub
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jul 2026 00:39
- Source
- TradingView
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
Investing.com UK
Direct company coverage
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com
This article announces the filing of a Form 4 for Alaunos Therapeutics Inc. on July 2nd. It is a brief financial news update from Investing.com, providing no further details within the article text itself.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 22:38
- Source
- Investing.com UK
Stock Titan
Direct company coverage
Stock grant to Alaunos (TCRT) CEO issued in lieu of salary
Alaunos Therapeutics (TCRT) CEO Holger Weis received a stock grant of 3,880 common shares on June 30, 2026, as compensation in lieu of net salary. The shares were valued at $2.26 each, and following this transaction, Weis directly holds 16,552 common shares. This insider transact
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 21:11
- Source
- Stock Titan
dars.gov.et
Direct company coverage
TCRT Q4 2023 Earnings: Miss on EPS as Alaunos Continues Pre-Clinical Development - Earnings Per Share
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 30 Jun 2026 07:37
- Source
- dars.gov.et
Sahm
Direct company coverage
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
Alaunos Therapeutics announced new preclinical data for its metabolic candidate ALN1003, showing lower liver weight in treated mice after adjusting for body fat percentage in a diet-induced obesity study. This finding supports previous data indicating ALN1003's potential for live
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 30 Jun 2026 06:40
- Source
- Sahm
Stock Titan
Direct company coverage
Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings
Alaunos Therapeutics announced new preclinical data for its investigational drug ALN1003, showing it significantly reduced liver weight in a diet-induced obesity mouse study, even after adjusting for body fat percentage. This finding is consistent with earlier data indicating low
- Tone
- Positive 63/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 12:41
- Source
- Stock Titan
Stock Titan
Direct company coverage
Alaunos Therapeutics (TCRT) Stock News
This page provides news and updates for Alaunos Therapeutics (TCRT) stock, focusing on its transition from TCR-T cell therapy to small-molecule therapeutics for obesity. Recent updates highlight preclinical results for ALN1003, an oral candidate for obesity, showcasing positive m
- Tone
- Positive 65/100
- Event
- Earnings
- Published
- 29 Jun 2026 05:40
- Source
- Stock Titan
TradingView
Direct company coverage
Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT)
This article provides an overview of Alaunos Therapeutics, Inc. (NASDAQ: TCRT) financials and stock performance. It includes details on historical and estimated financial data, stock price movements, volatility, net income, and upcoming earnings dates. The company currently has 1
- Tone
- Negative 19/100
- Event
- Earnings
- Published
- 26 Jun 2026 08:10
- Source
- TradingView
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis
Alaunos Therapeutics Inc (TCRT) has a current financial score of 7.32, ranking 126th out of 387 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue saw a 100% year-over-year decr
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 24 Jun 2026 16:10
- Source
- TradingKey
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Valuation: PE, PB & Fair Value Analysis
Alaunos Therapeutics Inc (TCRT) currently has a valuation score of 6.29, placing it low within the Biotechnology & Medical Research industry. The company's P/E ratio is -1.04, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P
- Tone
- Negative 35/100
- Event
- Market update
- Published
- 19 Jun 2026 04:09
- Source
- TradingKey
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Alaunos Therapeutics Inc (TCRT), detailing its price momentum score of 5.75 and positioning between resistance at $2.85 and support at $1.68. It includes a summary of technical indicators and moving averages, which overwhelmingly sugg
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 19 Jun 2026 02:09
- Source
- TradingKey
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Alaunos Therapeutics Inc (TCRT), noting that no earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.15. The report also indicates that re
- Tone
- Negative 41/100
- Event
- Earnings
- Published
- 18 Jun 2026 13:40
- Source
- TradingKey
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Alaunos Therapeutics Inc (TCRT), identifying its major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity, including ch
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 11:09
- Source
- TradingKey
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Alaunos Therapeutics Inc (TCRT) stock split history and dividend payouts. The company has not distributed any dividends over the past five years. However, it has had several merger-related stock splits, including a 10-for-1 merger in July 2024
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 03:09
- Source
- TradingKey
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown for Alaunos Therapeutics Inc (TCRT), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents the current stock price, market cap, a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 02:09
- Source
- TradingKey
Stock Titan
Direct company coverage
Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary
Alaunos Therapeutics CEO Holger Weis received a stock grant of 7,761 common shares valued at $2.26 per share on June 12, 2026. This grant was issued in lieu of his net salary, not through an open-market purchase. Following this transaction, Weis directly holds 12,672 shares of Al
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 20:39
- Source
- Stock Titan
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Institutional Confidence
This article from TradingKey provides an overview of Alaunos Therapeutics Inc (TCRT)'s institutional confidence score, financial data, and shareholder activity. It lists key institutional shareholders and their recent changes in shareholdings, showing that some increased their st
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 02:39
- Source
- TradingKey
TradingKey
Direct company coverage
Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Alaunos Therapeutics Inc (TCRT), detailing its volatility, financial risk, and investment risk. It highlights the company's beta value of -1.06, indicating it tends to underperform in rising markets but declines less in falling ones. Th
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 15 Jun 2026 12:39
- Source
- TradingKey
TradingView
Direct company coverage
Number of shareholders of Alaunos Therapeutics, Inc. – NASDAQ:TCRT
The article concerns the number of shareholders for Alaunos Therapeutics, Inc. (NASDAQ:TCRT). It provides a snapshot of the company's financial overview on TradingView, indicating no trades and a closed market status. The content primarily lists navigation elements and disclaimer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jun 2026 02:09
- Source
- TradingView
Bez Kabli
Direct company coverage
Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk
Alaunos Therapeutics (TCRT) stock fell 6.9% due to concerns over its limited cash reserves and an impending Nasdaq delisting risk, as its market cap is below compliance requirements. The company is attempting to shift investor focus to ALN1003, an early-stage obesity drug, despit
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 04 Jun 2026 13:09
- Source
- Bez Kabli
Finviz
Direct company coverage
TCRT - Alaunos Therapeutics Inc Stock Price and Quote
This article provides comprehensive financial data, stock performance metrics, and a news feed for Alaunos Therapeutics Inc (TCRT). It includes details on the company's oncology-focused cell therapy developments, recent preclinical study results for ALN1003, and past analyst rati
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 30 May 2026 18:11
- Source
- Finviz
Stock Titan
Direct company coverage
Alaunos Therapeutics (TCRT) CEO takes 3,700 shares instead of salary
Alaunos Therapeutics (TCRT) CEO Holger Weis received 3,700 shares of common stock at $2.37 per share on May 22, 2026, as compensation in lieu of his net salary. Following this transaction, Weis directly holds 4,911 shares of Alaunos common stock. This insider activity was reporte
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 20:39
- Source
- Stock Titan
MSN
Direct company coverage
Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers
Alaunos Biomedical announced positive preclinical results for its new obesity drug, which demonstrated significant reductions in body weight, improved liver health, and enhanced insulin sensitivity in animal models. These findings suggest the drug could be a promising candidate f
- Tone
- Positive 86/100
- Event
- Earnings
- Published
- 27 May 2026 17:39
- Source
- MSN
Investing.com South Africa
Direct company coverage
Alaunos reports preclinical data for obesity drug candidate ALN1003 By Investing.com
Alaunos Therapeutics has released integrated preclinical data for its oral obesity drug candidate, ALN1003, showing significant body weight and liver weight reductions in diet-induced obesity mouse studies. Despite these promising results and potential benefits for metabolic issu
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 26 May 2026 17:10
- Source
- Investing.com South Africa
GlobeNewswire
Direct company coverage
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 15:01
- Source
- GlobeNewswire
Quiver Quantitative
Direct company coverage
Alaunos Therapeutics Reports Positive Preclinical Results for ALN1003 in Addressing Metabolic Disease Markers
Alaunos Therapeutics announced positive preclinical results for ALN1003, an oral treatment for obesity and metabolic disorders, showing significant reductions in body weight and fat mass, improved insulin sensitivity, and enhanced liver health in diet-induced obese mice. While th
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 26 May 2026 15:11
- Source
- Quiver Quantitative